Bionik Laboratories Corp., often referred to as Bionik, is a pioneering company headquartered in the United States, specialising in the development of innovative robotic rehabilitation solutions. Founded in 2015, Bionik has made significant strides in the healthcare industry, focusing on enhancing recovery for individuals with neurological and mobility impairments. The company operates primarily in North America and Europe, offering advanced robotic systems designed to improve patient outcomes through engaging and effective rehabilitation therapies. Bionik's flagship products, including the ARKE and the InMotion robotic systems, stand out for their unique integration of robotics and artificial intelligence, providing tailored therapy experiences. With a commitment to transforming rehabilitation practices, Bionik Laboratories has established a strong market position, recognised for its contributions to the field of robotic-assisted therapy and its dedication to improving the quality of life for patients worldwide.
How does Bionik Laboratories Corp.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bionik Laboratories Corp.'s score of 18 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bionik Laboratories Corp., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Bionik Laboratories may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives at this time. As the company operates within a sector increasingly focused on sustainability, it may benefit from developing clear climate commitments and reduction strategies to align with broader industry trends.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bionik Laboratories Corp. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

